Nasopharyngeal carriage studies provide insights into the local prevalence of circulating pneumococcal serotypes. These data are critical for vaccination monitoring purposes, as they allow predicting and assessing their impact. Scarce data are available on the carriage of pneumococcal serotypes in Morocco. Here, we describe the prevalence of Streptococcus pneumonia carriage and serotype distribution among195 healthy infants and young children recruited at a vaccination clinic and 697 pediatric patients aged from 2 to 59 months admitted to a Moroccan reference hospital with severe pneumonia. Carriage rates were 40.5% (79/195) for healthy children and 22.8% (159/697) among sick ones. Most frequent circulating serotypes included 6A, 6B and 19F all included in the current 13-valent anti-pneumococcal conjugate vaccine recently introduced in the country. Monitoring of circulating serotypes remains necessary after vaccine introduction to assess whether serotype replacement is occurring.
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Background
Pneumococcal disease is the leading cause of vaccine preventable deaths and Streptococcus pneumoniae is estimated to be responsible for 11% of all deaths in children less than five years of age worldwide, mostly due to community-acquired pneumonia [1] .Nasopharyngeal colonization is known to play an important role in the development and transmission of pneumococcal disease. Infants and young children are considered to be the main reservoir of this pathogen [2] .Studies show that it is essential to monitor prospectively the pneumococcal circulating serotypes to predict and assess the impact of the vaccine introduction in a given community and also to allow the demonstration of whether serotype replacement may be occurring [3] .
In Morocco, a middle-income country in Northern Africa, pediatric pneumonia remains a major public health challenge. A recent study conducted in 2010 in a tertiary hospital among admitted children under five years of age with clinically severe pneumonia, reported that the etiologies of pneumonia were mostly viral, and that bacterial pathogens were rarely isolated, affecting only 3.5% of the patients [4] . The Moroccan Ministry of Health introduced in 2010 the pneumococcal (13-valent) conjugate vaccines into its expanded program of immunization (EPI) schemes among other control measures [5] . Due to the scarce available data in Morocco [6] , we aimed to investigate pneumococcal carriage and serotype distribution among healthy infants recruited at vaccination clinics and sick children admitted with a diagnosis of severe pneumonia at a referral tertiary hospital in Morocco.
Material and methods
Study area and population
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The study was conducted at the Hôpital d'Enfants de Rabat (HER)-the only public hospital dedicated to children in the region-and at four heath centers located in the area of Rabat-Salé-Zemmour-Zair (RSZZ Rabat province). The proportion of children under five in the region of RSZZ has been estimated at 5.66% [5] .
Study design
The study population was recruited from HER among patients admitted for severe clinical pneumonia according to WHO definition [7] during a one-year survey from November 2010 to December 2011, as part of a wider research protocol trying to define the epidemiology and etiology of respiratory distress at HER [4] . Healthy children who were visiting primary health care centers of the province of Rabat for routine vaccination were also recruited from February to March 2011. These sites were selected randomly from the list of the primary health care of the region RSZZ. The sample size for the community study (n=200) was calculated based on the preliminary carriage rates found at HER in children with WHOdefined severe clinical pneumonia [4] .
Data collection
Children were recruited both at the wards of HER or at the health centres only after an informed consent was signed by parents or legal guardians. The study team would then administer standardized questionnaires and obtain nasopharyngeal samples from the children using a mini culturette extra-thin flexible wire swab with its tip, in addition to other procedures explained elsewhere [4] .
Laboratory methods
The nasopharyngeal cultures were injected into Stuart transport medium tubes. Samples were processed on a daily basis: homogenized, aliquoted, and frozen at -70ºC. Nasal samples were cultured using conventional methods and bacterial isolates were identified by colony [8] .
Data analysis
Study variables were counted and summarized in frequency tables. Quantitative variables are summarized as Means with their corresponding standard deviations. Qualitative variables are presented as a percentage with 95% confidence interval. As the inclusion of patients from the peripheral health posts was only conducted to provide a baseline assessment of carriage rates among theoretically healthy children, but was not designed to infer differences or associations, no formal statistical comparisons are presented between both groups.
Results
Seven hundred patients were admitted for severe clinical pneumonia during the one-year survey and were eligible for the study, and 200 healthy children were recruited from primary health care centers during one month. The proportion of infants less than 1 year of age, was 30.6% (214/700) among the admitted patients and 70.7% (138/195) in children from the community. Three samples from the hospitalized group and five from the outpatient group were not suitable for analyses. Thus, nasopharyngeal carriage of streptococcus pneumonia among admitted patients was 22.8% (159/697), and 40.5% (79/195) among children attending the primary care centers.
Among admitted patients, monthly distribution of carriage was significantly different (data not shown, p<0.001), and carriage was significantly more frequent during spring and summer 6 (~31-32%) than during autumn or winter (~19-20%) (p=0.003). Seasonality could not be assessed among outpatients as recruitment lasted only one month.
Carriage rates also varied, albeit no significantly, according to number of doses received of pneumococcal vaccine. Thus, in infants, carriage rates were 21.2%, 24.5%, 31.3% and 33% among those not having received any dose, 1, 2 or three doses respectively. 24.0% and 31.6% of the children aged over one year and not having received any dose or one dose, respectively, were carriers, while none of those having received at least two doses were positive. Table 1 shows the characteristics of the children included in this study and the distribution of serotypes according to the status group.
Discussion
This study showed a moderately low nasal carriage of pneumococci, ranging from 23% to 40% in two very distinct pediatric populations, namely sick children with clinical severe pneumonia and healthy children. This analysis gives baseline information of the current status of pneumococcal carriage among children in Morocco, although it is worth noting that the two groups studied do differ significantly in some important variables, such socioeconomic status or exposure to antibiotics or smoking. These differences probably reflect different patterns of health seeking behavior at the health post and hospital level.
The predominant serotypes identified in these population were 6A, 19F/B/C, 6B, 23A and 23F serotypes. This result could be explained by the fact that the samples were obtained shortly after the introduction of the vaccine in the EPI schedule. Similar results were found in the Region of Marrakech among healthy children [9] and admitted patients in Casablanca [10] .
At least half of the individual serotypes identified are included in the current vaccine used by the national immunization program introduced in November 2010 [11] . Actual coverage of circulating serotype of this vaccine in Morocco may be even higher, as some of the grouped serotypes identified are also included in the vaccine. Consequently, the wider implementation of this vaccine, for which coverage rates were still low among admitted patients with severe pneumonia at the time of the study, may not only contribute to the observed decreased pneumococcal associated severe disease, but also asymptomatic carriage [12] . The potential public health impact of this vaccine, once it has been adequately deployed throughout the country, seems therefore significant. In low and middle-income countries, and under natural conditions of exposure, children become quickly colonized by pneumococci, and it is not uncommon to find moderate to high carriage rates (often exceeding 2/3 of the children) in countries that have not yet implemented vaccinations program, particularly among young infants [13] . In our study, we found lower than expected carriages rates of those serotypes most commonly described in the literature [13] . Continuous monitoring and repeated investigations for the serotype distribution of pneumococcal carriage and invasive disease remains necessary in Morocco, to adequately detect the emergence of new circulating serotypes [14] and prevent further morbidity and mortality as well as assess the impact of the recently implemented vaccine. 
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